{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:18:40Z","timestamp":1791177520028,"version":"4.1.0"},"reference-count":54,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The mechanism of action of AFN-1252, a selective inhibitor of\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n                    enoyl-acyl carrier protein reductase (FabI), which is involved in fatty acid biosynthesis, was confirmed by using biochemistry, macromolecular synthesis, genetics, and cocrystallization of an AFN-1252\u2013FabI complex. AFN-1252 demonstrated a low propensity for spontaneous resistance development and a time-dependent reduction of the viability of both methicillin-susceptible and methicillin-resistant\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    , achieving a \u22652-log\n                    <jats:sub>10<\/jats:sub>\n                    reduction in\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    counts over 24 h, and was extremely potent against clinical isolates of\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , 0.015 \u03bcg\/ml) and coagulase-negative staphylococci (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , 0.12 \u03bcg\/ml), regardless of their drug resistance, hospital- or community-associated origin, or other clinical subgroup. AFN-1252 was orally available in mouse pharmacokinetic studies, and a single oral dose of 1 mg\/kg AFN-1252 was efficacious in a mouse model of septicemia, providing 100% protection from an otherwise lethal peritoneal infection of\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    Smith. A median effective dose of 0.15 mg\/kg indicated that AFN-1252 was 12 to 24 times more potent than linezolid in the model. These studies, demonstrating a selective mode of action, potent\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity, and\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy, support the continued investigation of AFN-1252 as a targeted therapeutic for staphylococcal infections.\n                  <\/jats:p>","DOI":"10.1128\/aac.01411-12","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T02:53:01Z","timestamp":1346813581000},"page":"5865-5874","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":116,"title":["Mode of Action,\n                    <i>In Vitro<\/i>\n                    Activity, and\n                    <i>In Vivo<\/i>\n                    Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor"],"prefix":"10.1128","volume":"56","author":[{"given":"Nachum","family":"Kaplan","sequence":"first","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Albert","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Awrey","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Bardouniotis","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judd","family":"Berman","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Clarke","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Dorsey","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Hafkin","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaillal","family":"Ramnauth","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Romanov","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly B.","family":"Schmid","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Thalakada","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Yethon","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Pauls","sequence":"additional","affiliation":[{"name":"Affinium Pharmaceuticals, Inc., Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008305"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nsmb899","article-title":"Structure and molecular organization of mammalian fatty acid synthase","volume":"12","author":"Asturias FJ","year":"2005","unstructured":"AsturiasFJ. 2005. Structure and molecular organization of mammalian fatty acid synthase. Nat. Struct. Mol. Biol. 12:225\u2013232.","journal-title":"Nat. Struct. Mol. Biol."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5295.2107"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08667"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8284673"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1996.0689r.x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37485-9"},{"key":"e_1_3_3_9_2","volume-title":"47th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Brenwald NP","year":"2007","unstructured":"BrenwaldNP AndrewsJ FraisAP. 2007. Activity of AFN-1252 against Staphylococcus aureus showing reduced susceptibility to triclosan, abstr. F1-926. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07772"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.305"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058023"},{"key":"e_1_3_3_13_2","first-page":"752","volume-title":"Antibiotics in laboratory medicine","author":"Cleeland R","year":"1991","unstructured":"CleelandR SquiresE. 1991. Evaluation of new antimicrobials in vitro and in experimental animal infections, p 752\u2013783. In LorianV (ed), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, MD.","edition":"3"},{"key":"e_1_3_3_14_2","volume-title":"CLSI document M07-A7.","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed, vol 29. CLSI document M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"7"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444994003112"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/bj3570263","article-title":"Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data","volume":"357","author":"Cort\u00e9s A","year":"2001","unstructured":"Cort\u00e9sA CascanteM C\u00e1rdenasML Cornish-BowdenA. 2001. Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data. Biochem. J. 357:263\u2013268.","journal-title":"Biochem. J."},{"key":"e_1_3_3_17_2","volume-title":"The PyMOL molecular graphics system.","author":"Delano WL","year":"2002","unstructured":"DelanoWL. 2002. The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CA."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/587907"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1509.081228"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444904019158"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3343-3347.2002"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2002.02832.x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012775390-4\/50153-6"},{"issue":"2","key":"e_1_3_3_24_2","first-page":"60","article-title":"Methicillin-resistant Staphylococcus aureus: a descriptive analysis on veterans","volume":"83","author":"Hall LE","year":"1990","unstructured":"HallLE KleinEG SlaterLN FlournoyDJ. 1990. Methicillin-resistant Staphylococcus aureus: a descriptive analysis on veterans. J. Okla. State Med. Assoc. 83(2):60\u201363.","journal-title":"J. Okla. State Med. Assoc."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.44.26538"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/35018162"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005611200"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-001-0918-z"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.46.30316"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00400-09"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01254-06"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1074\/jbc.M406848200","article-title":"Determination of selectivity and efficacy of fatty acid synthesis inhibitors","volume":"280","author":"Kodali S","year":"2005","unstructured":"KodaliS. 2005. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J. Biol. Chem. 280:1669\u20131677.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/ar700156e"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708171200"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.11.5113-5120.2003"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/28970"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1086"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm020050"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume-title":"Methods in enzymology, vol 276: macromolecular crystallography, part A.","author":"Otwinowski Z","year":"1997","unstructured":"OtwinowskiZ MinorW. 1997. Processing of X-ray diffraction data collected in oscillation mode, p 307\u2013326. In CarterCWJr SweetRM (ed), Methods in enzymology, vol 276: macromolecular crystallography, part A. Academic Press, Inc., New York, NY."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1109208108"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3118-3124.2002"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(01)01774-3"},{"key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/prot.22581","article-title":"Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan","volume":"78","author":"Priyadarshi A","year":"2010","unstructured":"PriyadarshiA KimEE HwangKY. 2010. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan. Proteins 78:480\u2013486.","journal-title":"Proteins"},{"key":"e_1_3_3_45_2","volume-title":"51st Intersci. Conf. Antimicrob. Agents Chemother.","author":"Pulse ME","year":"2011","unstructured":"PulseME. 2011. Effects of AFN-1252 on in vitro and in vivo Staphylococcus aureus virulence gene expression, abstr. B-1763. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.07.094"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1303\/aez.33.339"},{"key":"e_1_3_3_48_2","volume-title":"PriProbit","author":"Sakuma M","year":"2005","unstructured":"SakumaM. 2005. PriProbit, 1.63 ed. M. Sakuma, Kyoto, Japan.","edition":"1"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.07.129"},{"issue":"3","key":"e_1_3_3_50_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-97-3-325","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks","volume":"97","author":"Saravolatz LD","year":"1982","unstructured":"SaravolatzLD PohlodDJ ArkingLM. 1982. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann. Intern. Med. 97(3):325\u2013329.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2012.03.013"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/S0960-894X(01)00405-X","article-title":"Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents","volume":"11","author":"Seefeld MA","year":"2001","unstructured":"SeefeldMA. 2001. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 11:2241\u20132244.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/48.1.1","article-title":"Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus","volume":"48","author":"Slater-Radosti C","year":"2001","unstructured":"Slater-RadostiC. 2001. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48:1\u20136.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_54_2","volume-title":"46th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Tsuji BT","year":"2006","unstructured":"TsujiBT. 2006. Bactericidal activity of API-1252, a novel bacterial enoyl-ACP reductase inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model, abstr F1-0758. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.171.12.6555-6565.1989"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01411-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01411-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:05:39Z","timestamp":1645463139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01411-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.01411-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01411-12","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717956114.793461923","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}